Quality control must be the watchword for any organization that manufactures APIs and other chemicals.
Aside from required FDA guidelines, this can mean different things to different organizations.
What is key, however, is an unwavering commitment to ensuring quality in every phase – from clean room operations, to calibration of instruments and preventative maintenance in utility systems. It’s essential that companies have processes and controls that help meet their own strict standards, as well as industry regulations.
Yet, while quality control is a given and experience is important, there will always be problems that arise in the lab or plant that derail even the best-laid plans. Many are out of the control of anyone – bad raw materials, equipment malfunction or the chemistry can simply not behave at larger scale despite good batches earlier in the Kilo Lab.
While such problems require that sponsoring firms pay additional fees to the Contract Manufacturing Organization (CMO), it’s not something that CMOs can bank on. In fact, they strive to avoid cost overruns, for the following reasons:
They derail the project pipeline. When one project goes over expected completion dates, it pushes back all other projects in the pipeline, creating a huge headache for management, which must explain why other projects can’t begin on time.
Not only does it affect current project schedules, but it may affect projects in the pipeline. Extending a project may generate a small cost-overrun, but the CMO may have to turn away a huge project because of the backlog
They derail equipment schedules. When a cost-overrun occurs, it is easy to add additional chemists to the job, yet equipment and vessels in the plant are under a carefully orchestrated usage schedule. Such equipment may be scheduled for different projects, and a delay in one project can create a cascade of delays, throwing off the schedule completely.
So, what can CMOs and sponsoring companies do to lessen the effects of cost overruns?
In the end, CMOs grow their business by helping APIs and other chemical entities become commercialized and solve critical healthcare needs. Cost overruns only delay the goals of CMOs and their sponsors, so sound attention to what can be done to prevent them, and sound action to address what is out of their control is key.